{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:07:18Z","timestamp":1782983238675,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"PhD program of Magna Graecia University: \u201cmolecular oncology and translational and innovative medical and surgical techniques\u201d"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.critrevonc.2018.08.011","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T12:00:39Z","timestamp":1535976039000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["The Era of PARP inhibitors in ovarian cancer: \u201cClass Action\u201d or not? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"131","author":[{"given":"Nicoletta","family":"Staropoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Iuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cuc\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grillone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Salvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-2008","authenticated-orcid":false,"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2018.08.011_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00280-015-2916-3","article-title":"Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis","volume":"77","author":"Arbitrio","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"33","key":"10.1016\/j.critrevonc.2018.08.011_bib0010","doi-asserted-by":"crossref","first-page":"54028","DOI":"10.18632\/oncotarget.9927","article-title":"DMET (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine","volume":"7","author":"Arbitrio","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.08.011_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2753.2010.01516.x","article-title":"Assessment of study quality for systematic reviews: a comparison of the cochrane collaboration risk of Bias tool and the effective public health practice project quality assessment tool: methodological research","volume":"18","author":"Armijo-Olivo","year":"2012","journal-title":"J. Eval. Clin. Pract."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.08.011_bib0020","first-page":"158","article-title":"Two-tailed Fisher\u2019s exact test (Cochran-Mantel-Haenzel)","volume":"2","author":"Balasubramaniam","year":"2002","journal-title":"Spine J."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.08.011_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/humu.1167","article-title":"Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast\/ovarian cancer","volume":"18","author":"Baudi","year":"2001","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-1-4419-9019-8_23","article-title":"STATA: a statistical analysis system for examining biomedical data","volume":"537","author":"Boston","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.08.011_bib0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","article-title":"Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients","volume":"1","author":"Botta","year":"2017","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.08.011_bib0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"7353","key":"10.1016\/j.critrevonc.2018.08.011_bib0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.08.011_bib0050","first-page":"1849","article-title":"Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Ciliberto","year":"2012","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.08.011_bib0055","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejca.2012.08.019","article-title":"Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials","volume":"49","author":"Ciliberto","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.08.011_bib0060","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1080\/15384047.2015.1056415","article-title":"A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?","volume":"16","author":"Ciliberto","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.08.011_bib0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pan.2016.01.003","article-title":"Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer","volume":"16","author":"Ciliberto","year":"2016","journal-title":"Pancreatology"},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2018.03.003","article-title":"The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: a classic and Bayesian meta-analysis","volume":"125","author":"Ciliberto","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10106","key":"10.1016\/j.critrevonc.2018.08.011_bib0075","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.critrevonc.2018.08.011_bib0080","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood-2010-05-280883","article-title":"Systematic review and meta-analysis methodology","volume":"116","author":"Crowther","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.08.011_bib0085","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jama.282.7.664","article-title":"Resolving discrepancies between a meta-analysis and a subsequent large controlled trial","volume":"282","author":"DerSimonian","year":"1999","journal-title":"JAMA : the journal of the American Medical Association"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.08.011_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0895-4356(92)90085-2","article-title":"Incorporating variations in the quality of individual randomized trials into meta-analysis","volume":"45","author":"Detsky","year":"1992","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.08.011_bib0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.2011.08622.x","article-title":"A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling","volume":"154","author":"Di Martino","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.08.011_bib0100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4161\/cbt.12.9.17781","article-title":"Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study","volume":"12","author":"Di Martino","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"52","key":"10.1016\/j.critrevonc.2018.08.011_bib0105","doi-asserted-by":"crossref","first-page":"85895","DOI":"10.18632\/oncotarget.13135","article-title":"Genetic variants associated with gastrointestinal symptoms in Fabry disease","volume":"7","author":"Di Martino","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0110","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.17613","article-title":"Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting","author":"Dougherty","year":"2017","journal-title":"Oncotarget"},{"issue":"5 Suppl. 15","key":"10.1016\/j.critrevonc.2018.08.011_bib0115","article-title":"Carboplatin\/paclitaxel versus cisplatin\/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group","volume":"24","author":"du Bois","year":"1997","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.08.011_bib0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1758834016687254","article-title":"PARP inhibitors in ovarian cancer: evidence, experience and clinical potential","volume":"9","author":"Evans","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2105-13-258","article-title":"DMET-analyzer: automatic analysis of Affymetrix DMET data","volume":"13","author":"Guzzi","year":"2012","journal-title":"BMC Bioinformatics"},{"issue":"12","key":"10.1016\/j.critrevonc.2018.08.011_bib0130","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/sim.3602","article-title":"Extending DerSimonian and Laird\u2019s methodology to perform multivariate random effects meta-analyses","volume":"29","author":"Jackson","year":"2010","journal-title":"Stat. Med."},{"issue":"9951","key":"10.1016\/j.critrevonc.2018.08.011_bib0135","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.08.011_bib0140","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum. Pathol."},{"issue":"Suppl. 7","key":"10.1016\/j.critrevonc.2018.08.011_bib0145","doi-asserted-by":"crossref","first-page":"vii218","DOI":"10.1093\/annonc\/mdq377","article-title":"Optimal treatment for relapsing ovarian cancer","volume":"21","author":"Ledermann","year":"2010","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2018.08.011_bib0150","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.08.011_bib0155","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2016.71.3677","article-title":"Somatic BRCA1\/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition","volume":"35","author":"Lheureux","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.08.011_bib0160","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tjog.2017.08.026","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer","volume":"56","author":"Liu","year":"2017","journal-title":"Taiwan J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.08.011_bib0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.08.011_bib0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13048-016-0238-7","article-title":"Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients","volume":"9","author":"Mignogna","year":"2016","journal-title":"J. Ovarian Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2018.08.011_bib0175","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.08.011_bib0180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-018-3532-9","article-title":"PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer","volume":"81","author":"Morgan","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"24","key":"10.1016\/j.critrevonc.2018.08.011_bib0185","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \"BRCAness\" sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020712-163949","article-title":"Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma","volume":"9","author":"Nik","year":"2014","journal-title":"Annu. Rev. Pathol."},{"issue":"19","key":"10.1016\/j.critrevonc.2018.08.011_bib0195","doi-asserted-by":"crossref","first-page":"19643","DOI":"10.1074\/jbc.M311780200","article-title":"BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition","volume":"279","author":"Ouchi","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.08.011_bib0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2018.08.011_bib0205","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.08.011_bib0210","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2018.08.011_bib0215","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2217\/fon-2016-0189","article-title":"Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients","volume":"12","author":"Pinto","year":"2016","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.08.011_bib0220","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0225","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An effective Epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA-mutations","author":"Pulliam","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"64","key":"10.1016\/j.critrevonc.2018.08.011_bib0230","doi-asserted-by":"crossref","first-page":"107558","DOI":"10.18632\/oncotarget.22505","article-title":"Genetic variants associated with Fabry disease progression despite enzyme replacement therapy","volume":"8","author":"Scionti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0235","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.08.011_bib0240","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4161\/cbt.28557","article-title":"Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials","volume":"15","author":"Staropoli","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"50","key":"10.1016\/j.critrevonc.2018.08.011_bib0245","doi-asserted-by":"crossref","first-page":"82741","DOI":"10.18632\/oncotarget.12633","article-title":"Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation","volume":"7","author":"Staropoli","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.08.011_bib0250","first-page":"61","article-title":"Meta-analyses and large randomized, controlled trials","volume":"338","author":"Stewart","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2018.08.011_bib0255","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA :J. Am. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2018.08.011_bib0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1757-2215-2-14","article-title":"BRCA1\/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?","volume":"2","author":"Tagliaferri","year":"2009","journal-title":"J. Ovarian Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.08.011_bib0265","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2018.08.011_bib0270","first-page":"1257","article-title":"Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents","volume":"26","author":"Tassone","year":"2005","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.08.011_bib0275","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/cbt.8.7.7968","article-title":"Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo","volume":"8","author":"Tassone","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.08.011_bib0280","doi-asserted-by":"crossref","first-page":"285","DOI":"10.18632\/oncotarget.12306","article-title":"Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.08.011_bib0285","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-03-2907","article-title":"Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:27:36Z","timestamp":1760902056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818302506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":57,"alternative-id":["S1040842818302506"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.08.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Era of PARP inhibitors in ovarian cancer: \u201cClass Action\u201d or not? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}